

KVARTALSRAPPORT

Q2

April - June 2026

THE FOUNDATION HAS BEEN LAID. NOW THE JOURNEY REALLY BEGINS.

During the quarter, ZymIQ has focused on completing preparations for the company's planned listing on Nasdaq First North Growth Market. The work has included renegotiation of strategically important agreements, strengthened company structure, balance sheet measures and financing preparations to create the best possible conditions for the next phase of growth. In parallel, the marketing plans for Kalzyme and DentaPrev have continued to be implemented. With a strengthened platform, a cleaner balance sheet and a clearer path forward, the company believes that the foundation is now laid to begin the next chapter in ZymIQ's development.

1 JAN – 30 JUNE 2026

- Net sales
  amounted to SEK 848 thousand (1,146)
- Loss after tax
  amounted to SEK -9,103 thousand (-5,212)
- Earnings per share
  amounted to SEK -0.98 (–0.61)
- Cash and cash equivalents
  amounted to SEK 1,010 thousand (888)

Q2 - 1 APRIL – 30 JUNE 2026

- Net sales
  amounted to SEK 13 thousand (334)
- Loss after tax
  amounted to SEK -5,477 thousand (-3,149)
- Earnings per share
  amounted to SEK -0.58 (–0.37)

SIGNIFICANT EVENTS DURING THE REPORTING PERIOD

- ZymIQ has been granted a patent in Japan for its exclusive enzyme-based technology to prevent and break down microbial biofilms.
- Important article about ZymIQ BioPharma's work was published in the respected journal Trend of Microbiology. An important recognition of the research.
- The article has in turn attracted other researchers who write about the article. Yet another proof of the relevance of research.
- The product CombatClean is mentioned in the Home Guard's training book as a dental care product.
- ZymIQ's representatives attended major international trade fairs for defense and military, where the CombatClean brand could be showcased:
- Special Operations Medical Association Scientific Assembly (SOMA) - 2026 i Raleigh, NC, USA.
- SOF Week (Special Operation Forces) i Tampa, Florida, USA
- Finally, these major fairs ended with EUROSATORY in Paris, France
- Long-term tests with DentaPrev and CombatClean tablets showed a significantly longer shelf life, while retaining enzyme activity

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

- ZymIQ has signed an exclusive distribution agreement for Kalzyme® with the Swedish company Imazo AB. Imazo, founded in 1962 and is today one of the Nordic region's leading distributors in the pet trade. Imazo currently has over 1600 retail outlets in the Nordic region and even maintains its own fleet of vehicles for safe deliveries.
- The technology behind Kalzyme is approved in the United States, the world's largest pet market. The patent is also not limited to animals, but covers applications on the human side, including in oral health, dermatology and wound care, expanding the potential market far beyond pets.
- The company is taking out a short-term bridge loan to strengthen cash flow prior to listing.
- Application meeting Nasdaq

COMMENTS FROM THE CEO

Comments from the CEO – Q2 2026

Building the foundation for the next chapter

The second quarter of 2026 has largely been characterized by work that is rarely visible to the outside world, but which is absolutely crucial for a company's long-term development. My focus and that of the management has been to complete the preparations for our planned listing on Nasdaq First North Growth Market and at the same time ensure that ZymIQ is as strong as possible for the growth journey we are now preparing for.

During the quarter, we conducted a large number of meetings, reviewed structures, renegotiated agreements and made several strategic decisions to create the best possible conditions for the next 12 months. This work has also involved overall discussions on research and development, where we in some cases have chosen to write off historical receivables and older commitments in order to be able to create clearer, stronger and more long-term sustainable business relationships going forward.

For me, this is about traditional and necessary cleaning of the balance sheet. If a company is to grow seriously, the groundwork must be done. We want our structure, our agreements and our relationships to reflect the ambitions we have for the future, not the history behind us.

The work has also meant that the listing process has taken a little longer than we originally hoped for. Our assessment today is that the listing will not be carried out on the basis of the Q2 report, but that the next important milestone will instead be the Q3 report. At the same time, I feel a great sense of security in the fact that we are now entering that phase with significantly better conditions than before. With a cleaner balance sheet, stronger agreements and clearer processes, I see that we can soon start the next chapter for real.

A significant part of the quarter was also devoted to administration, corporate governance and the work of securing the bridge financing required to realize our plans. Financing is rarely what engages a company the most, but it is often what enables everything else. I am therefore very pleased that we are now in a better position to invest in our priority growth areas in a concrete, responsible and long-term manner.

In parallel with this, work on our marketing plan continues. We are preparing for the scale-up of Kalzyme in animal health while intensifying the work for the launch of the DentaPrev tablet through influencers, social media and other digital channels. The ambition is still to reach the market before Christmas. It is an aggressive timetable, but I still believe that it is achievable if we continue to work together in a focused manner.

All of this is also part of our IR work. We want to create awareness of ZymIQ, build trust and make the company relevant to both existing and future shareholders. At the time of writing, we feel confident with the plan we have developed and with our ability to deliver on it. At the same time, our ambition is to communicate significantly more closely with the market and our shareholders as soon as the timetable for the listing is finally anchored and agreed.

I would also like to take this opportunity to extend a warm thank you to all shareholders who contact us. The conversations, questions, advice, challenges and commitment mean more than many people might think. We care about our shareholders and see a future listing as the beginning of a common journey, not the end of one. For me, the listing is not about an exit. It is about creating better opportunities to build on what we have worked so hard together to create.

We are currently only twelve people in the organization. Despite this, we manage to advance our positions every day in research, animal health, oral health and business development. It's something I feel great respect and gratitude for. Behind every progress are people who invest their time, energy and heart in creating products that can contribute to a better everyday life for both people and animals.

Soon we will also activate our IR plan and look forward to a period where more people will have the opportunity to discover what ZymIQ actually builds.

A lot of work has been put in by many people to get us here. Now the final steps remain before we can fully focus on growth, profitability and value creation. I feel very confident about what lies ahead.

I am proud of the journey that has been written so far. But in all honesty, I think the most interesting chapters are still ahead of us.

Michael Edelborg Christensen
CEO, ZymIQ Technology AB (publ)

BUSINESS OVERVIEW

ABOUT THE COMPANY

ZymIQ is an innovative Life Science group, founded in 2020, by scientists, veterinarians and entrepreneurs.

ZymIQ Technology AB focuses on smart enzyme technology in health products intended for both humans and animals.

ZymIQ Biopharma AB is a wholly-owned subsidiary that develops the next generation of antimicrobial products using enzyme and phage technology that are more effective and less harmful than traditional treatments. In this way, ZymIQ is fighting the global threat of increased antibiotic resistance by developing new solutions that can potentially replace or complement future antibiotic treatments.

ZymIQ is headquartered at Medicon Village in Lund, Sweden, and also has offices in Virginia, USA, as well as representative offices in Singapore and Malaysia.

INTRODUCTION TO THE COMPANY'S OPERATIONS

ZymIQ has developed two unique research platforms to prevent current infections. ZymIQ's first platform protects healthy skin and mucous membrane, while the second platform fights ongoing current bacterial infections. Here, the enzymes act as high-precision tools that can target unwanted pathogens, while keeping the microbiome healthy and intact. With the potential for unique synergy effects, the platforms have the potential to deliver products that can replace conventional antibiotic treatment and thereby reduce the risk of antibiotic resistance.

In addition to advanced research, ZymIQ primarily develops enzyme-based oral care products for humans and animals. DentaPrev (www.dentaprev.com) is an innovative oral care brand that uses enzymes to prevent malignant bacteria from causing plaque, tartar and bad breath. Kalzyme (www.kalzyme.com), for dental and skin care in animals, prevents microbial adhesion and irritation and accelerates the healing process. DentaPrev and Kalzyme are also available in a B2G variant to be able to support societal functions related to health in military operations and crisis preparedness, here they go under the brand CombatClean. ZymIQ also has a partnership with the high-profile skincare brand fjör (www.fjor.life) that exclusively uses the company's technology platforms for the development of new products.FINANCIAL OVERVIEW

QUARTERLY EARNINGS DEVELOPMENT

All amounts in SEK thousand	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	13	835	356	400	334	812	269	268	328	416
Gross profit/loss	5	449	224	151	277	240	44	213	157	340
Gross margin in %	38%	54%	63%	38%	83%	30%	16%	79%	48%	82%
Operating profit/loss	-5 514	-3 658	-5 867	-1 029	-3 148	-2 104	-2 764	-2 942	-3 136	-2 205
Profit/loss for the period	-5 477	-3 626	-5 925	-1 030	-3 149	-2 063	-2 610	-3 008	-3 157	-2 179
Cash flow	488	-1 966	528	1 072	-1 369	-932	2 171	-3 951	4 245	-427

ZYMIQ BIOPHARMA

ZymIQ Biopharma AB is a wholly owned subsidiary of ZymIQ Technology AB with a focus on biologically engineered solutions for infection control and antibiotic resistance. The company develops enzyme-based and immunomodulatory technologies targeting resistant bacteria, chronic infections and viral threats, for both human and veterinary medicine. For more information, see www.zymiqbiopharma.com

PIPELINE

The company's development portfolio includes four programs: Mycolysis, an enzyme-based platform targeting drug-resistant mycobacteria such as tuberculosis and NTM lung infections. Stapholysis, an enzyme-based approach against pathogenic Staphylococcus species including MRSA. SPL, a phage-based immunomodulatory biologic in redevelopment for recurrent staphylococcus-driven skin infections in dogs, particularly associated with atopic dermatitis. ViruPrev, an enzyme-based mucosal barrier designed to reduce viral exposure at the nose and mouth.

STATUS ZYMIQ BIOPHARMA

During the second quarter, ZymIQ Biopharma continued its work to translate the scientific validation of Mycolysis into a clearer preclinical development and partnership plan. During the quarter, the company participated in the development of a complete international research application within the One Health Antimicrobial Resistance Partnership, OH-AMR. The project focuses on novel combination strategies against rifampicin-resistant tuberculosis and brings together academic environments with expertise in tuberculosis, drug resistance and preclinical infection models. At the end of the reporting period, the application was under evaluation.

In parallel, progress was made in the redevelopment of the SPL program for recurrent staphylococcus-driven skin infections in dogs. Together with a potential external manufacturing partner, comparative process tests were carried out regarding bacterial growth and phage-mediated lysis under animal component-free conditions. The work aims to establish a reproducible manufacturing process and enable the production of a first pilot batch for continued testing and evaluation of a sublingual product. After the scientific validation in the first quarter, ZymIQ Biopharma focused in Q2 on structuring the next development steps for the programs, including preclinical planning, manufacturing preparations and international research collaborations.

DENTAPREV

DentaPrev offers gentle and effective dental care that improves oral hygiene with the help of enzymes. With high-quality ingredients and enzymes, DentaPrev helps fight plaque, tartar, and bad breath. The portfolio includes dental spray and enzyme tablets.

DENTAPREV DENTAL SPRAY

DentaPrev Dental Spray is used to clean teeth and gums, maintain good oral hygiene, and freshen your breath throughout the day. The product improves your oral hygiene by creating a multifunctional barrier that prevents the adhesion of bacteria. At the same time, the oral microbiome is balanced.

The unique design of the bottle is adapted to the user's needs, where it should be easy and convenient to improve both their own and others' oral hygiene. The spray is intended for children, adults and the elderly for smooth, effective and gentle oral care.



DENTAPREV ENZYME TAB

DentaPrev Enzyme Tab is a new revolutionary solution for smooth oral hygiene, based on an advanced enzyme blend developed in collaboration with a globally leading partner in enzyme technology. The product is designed as a tablet that dissolves in the mouth and reduces plaque and balances the oral microbiome, as confirmed in clinical studies. A daily intake of three tablets gives an effect equivalent to about 60 seconds of conventional toothbrushing.

The product addresses a clear need for smooth oral hygiene in situations where traditional toothbrushing is not possible, while also offering a solution for consumers who want to optimize their oral health.



DentaPrev is now available with a sample-pack that is distributed primarily to stakeholders in the travel retail segment where discussions are starting to take shape.

COMBATCLEAN

The CombatClean brand has been developed to provide enzyme-based health products specifically adapted for military personnel and emergency services. Currently, the range includes Clean Teeth Enzyme Tab and Kalzyme K9 Dental Spray for service dogs. The ambition is to also include DentaPrev Dental Spray in the range.

CLEAN TEETH ENZYME TAB



The new 1pcs sampla

The Clean Teeth Enzyme Tab focuses on the military and Armed Forces where dental disease is one of the most common non-combat-related injuries during military operations, with 150-200 acute dental cases per 1,000 people annually in active duty forces. Dental problems often lead to staff having to be evacuated from their assignments, resulting in loss of time and strain on resources and negatively affecting operational readiness. CombatClean can play an important role in this by offering efficient and flexible dental care for the personnel out in the field.

K9 DENTAL ENZYME SPRAY



Keeping a dog's teeth clean and free of plaque is no easy task. Traditional toothbrushing is often a challenge, and the high cost of veterinary dentistry can add up quickly. Even worse, poor oral health can impair a K9's overall performance. That's why we now also offer K9 Dental Enzyme Spray, specifically designed for service dogs

The brand continues to be exposed more and more at trade shows and special events around the world.

The concept is slowly starting to establish itself and more people are starting to see the benefits. The work of mapping, informing and educating the various decision-makers that need to be reached continues.

KALZYME

Kalzyme is developed by veterinarians and animal health scientists. Kalzymes' unique enzyme technology is specifically developed to strengthen the natural defenses and reduce the risk of growth of harmful bacteria by breaking down biofilms. The product portfolio includes three products in the form of Dental Spray, Dermal Spray and Dermal Gel. Additional products are under development. Kalzyme is currently available for sale in the Southeast Asian markets and in Sweden and has been launched for veterinarians in the US in the autumn of 2025.



KALZYME DENTAL SPRAY

Kalzyme Dental Spray is a dental spray for dogs and cats. Dental Spray helps to counteract plaque and tartar build-up while supporting a healthy bacterial flora in the mouth and providing fresh breath.



KALZYME DERMAL SPRAY & GEL

Kalzyme Dermal Spray and Gel creates a soothing protective film around skin irritations, hotspots, redness and itching. At the same time, the skin is exfoliated and moisturized.

KALZYME OTIC DROPS - NEWS

Kalzyme has recently expanded its range with Kalzyme Otic Drops, a gentle and caring ear product that is specially developed to relieve irritation and effectively dissolve both wax and biofilm. By making use of natural enzyme technology, the product recreates a healthy environment in the ear by balancing the microbiome, making it suitable for daily and long-term use with no side effects for the pet.

The work of finding more customized distributors, instead of focusing on direct dealers as before, is both extensive and time-consuming. However, the time spent provides a deeper understanding of the products' conditions and of the potential that exists in each market. Finding the right partner for each market is therefore crucial, as it is in the right collaboration that the brand can be built in the long term.

Dialogues are already underway with several distributors in several markets at the same time, but it is important that the process is allowed to take the time it needs for the collaborations to really bear fruit. In parallel, the work of compiling training material for both sellers and the dealers that the distributors themselves work with continues.

PARTNERSHIP WITH FJÖR

fjör ZymIQ is an innovative skincare brand that uses ZymIQ's enzyme technology to strengthen the skin barrier and promote microbial diversity. The product range offers Hydrolytic serum, moisturizer and body lotion.





As previously communicated, ZymIQ has signed a new agreement with Fjör. The new agreement marks the start of a deeper collaboration with a focus on global expansion and product development. The agreement, which runs for 36 months with the possibility of extension, guarantees ZymIQ a fixed level of revenue throughout the period. This replaces the previous agreement between the parties and means that ZymIQ will now manufacture all products in fjörs range and be responsible for the development of new products. ZymIQ owns a minority stake in FJOR LTD.

FINANCIAL INFORMATION

COMPANY INFORMATION

ZymIQ Technology AB (publ), corporate identity number 559279–3631, is a Swedish-registered limited liability company with its registered office in Lund, Sweden, and which is the parent company of the ZymIQ Group. The address of the head office is Scheeletorget 1, 223 63 Lund. Wholly owned subsidiaries are ZymIQ Biopharma AB, Lund, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented through offices in Singapore and Malaysia.

THE SHARE

ZymIQ Technology AB (publ) intends to be listed on Nasdaq First North Growth Market. ISIN code: SE0016074306.

The number of shares at the end of the period was 9,399,672. All shares are of the same class and have the same voting rights.

SCOPE OF THE REPORT

This quarterly report covers the period from 1 April 2026 to 30 June 2026. All information in the report relates to the ZymIQ Group.

ORGANIZATION

At the end of the period, the Group had 12 employees, of which 7 were women and 5 men. The number of consultants is 1–2.

RESEARCH AND DEVELOPMENT

The development work is run in-house in collaboration with consultants and external clinics. The development work is focused on new development and further refinement of the current product portfolio.

DISPUTES

ZymIQ Technology is not a party to any legal dispute or arbitration. Nor is the Board aware of any circumstances that could lead to any such legal process being imminent.

INSURANCE

ZymIQ Technology has customary business insurance that also includes product liability coverage. The insurance cover is subject to continuous review. The Board of Directors assesses that the business insurance is adapted to the current scope of the business.

RISK FACTORS

ZymIQ Technology was formed in 2020. The company's contacts with both customers and suppliers are relatively short. A short history of operations can be expected to lead to an increased sensitivity to changes in the outside world. The short operating history also makes it more difficult to evaluate growth power and profitability targets. The risks that are primarily assessed to affect the company can be divided into market-related and company-specific risks. The market-related risks mainly consist of uncertainty regarding capital raising, market developments, political climate, competition, and suppliers and production. In addition to the short history, the largest company-specific risks are also found in clinical studies, organizational development, development costs, product liability and intellectual property rights.

CONDITIONS FOR CONTINUED OPERATION

This financial information has been prepared based on the going concern assumption. ZymIQ Technology has historically reported losses. In preparing the communiqué, management has based its assumptions on existing cash and cash equivalents, increased sales and the possibility of other financing. When estimating future expenses, management has taken into account that certain expenses are under management's control and can thus be eliminated or postponed to the future. Management is aware that there is uncertainty in the estimation of future cash flows as well as uncertainty in the financing of operations.

If ZymIQ Technology is unable to continue to operate the business for any reason, it may affect the Group's ability to realize the carrying amount of its assets, especially related to retained expenses for development work, as well as to pay debts at a normal pace and to the amounts recorded in the Group's quarterly report.

The company is dependent on additional financing to be able to complete its business plan. The Board of Directors and management assess that there are good opportunities to secure such financing, but it cannot be guaranteed that this will be done on terms favourable to the company or within the required time.

The management is fully aware of the company's capital needs and works in a structured and proactive way with financing, with the aim of securing capital in line with the company's continued commercialization, growth and scaling of already established business areas.

ANNUAL REPORT

The Annual Report for 2025 is available at the company.

ANNUAL GENERAL MEETING

The 2026 Annual General Meeting was held on 7 May in Lund. The protocol is available at ZymIQ Technology AB.

ACCOUNTING POLICIES

This report has been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines. The accounting policies and calculation methods applied are consistent with the accounting policies used in the preparation of the last annual report.

AUDITOR REVIEW

This report has not been reviewed by the company's auditor.

ZymIQ Technology AB
Lund, August 20, 2026

Board of Directors
Jonas Forsberg, Magnus Steen, Nicklas Persson
Rickard Ånell, Göran Strömberg

QUESTIONS ABOUT THE REPORT ARE ANSWERED BY
Michael Edelborg Christensen, CEO, ZymIQ Technology AB
Tel: +46 727-144 166
Mail: michael.christensen@zymiq.com

SUMMARY OF INCOME STATEMENT – GROUP

All amounts in SEK thousand	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating income					
Net sales	13	334	848	1 146	1 902
Cost of goods sold	-8	-57	-394	-629	-896
Gross profit	**5**	**277**	**454**	**517**	**1 006**
External expenses	-4 185	-1 556	-6 149	-2 904	-8 128
Staff expenses	-1 365	-2 029	-3 578	-3 335	-5 254
R&D Expenses	-1 191		-1 603	-816	-3 566
Capitalized development expenditure	1 191		1 603	816	3 566
Other operating income	61	166	131	476	551
Other operating expenses	-30	-6	-30	-6	-323
Operating profit/loss	**-5 514**	**-3 148**	**-9 172**	**-5 252**	**-12 148**
Profit/loss from financial items					
Interest income and similar profit/loss items	37	0	74	43	192
Interest expenses and similar profit/loss items	0	-1	-5	-3	-211
Profit/loss after financial items	**-5 477**	**-3 149**	**-9 103**	**-5 212**	**-12 167**
Tax expenses	-	-	-	-	-
Profit/loss for the period	**-5 477**	**-3 149**	**-9 103**	**-5 212**	**-12 167**
Share attributable to parent company shareholders	-5 477	-3 149	-9 103	-5 212	-12 167

Per share data	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Earnings per share, SEK (basic and diluted)	-0,58	-0,37	-0,98	-0,61	-1,39
Equity per share, SEK	1,61	2,23	1,61	2,09	2,38
Equity-asset ratio, %	59%	81%	59%	81%	86%
Number of outstanding shares	9 399 672	8 880 736	9 399 672	8 880 736	8 880 736
Average number of outstanding shares	9 399 672	8 664 412	9 313 183	8 610 331	8 745 534

KEY INDICATOR DEFINITIONS

Earnings per share. Profit for the period in relation to the average weighted number of shares

Equity per share. Equity in relation to the number of shares at the end of the period.

Solidity. Equity in relation to the balance sheet total.

CONSOLIDATED BALANCE SHEET IN BRIEF – GROUP

All amounts in SEK thousand	2026-06-30	2025-06-30	2026-03-31	2025-12-31
Assets				
Intangible assets	20 397	17 423	19 603	19 494
Property, plant & equipment	140	274	181	180
Inventories	1 971	1 846	1 871	1 997
Trade receivables	849	1 587	2 643	2 074
Other receivables	1 288	1 410	1 086	877
Cash and cash equivalents	1 010	888	522	2 488
Total assets	**25 655**	**23 428**	**25 906**	**27 110**
Equity and liabilities				
Equity	15 144	19 090	20 532	23 344
Interest-bearing liabilities, Long-term		0	0	0
Interest-bearing liabilities, Short-term	7 000	2 250	2 000	0
Trade payables	579	815	1 252	1 433
Other liabilities	2 932	1 273	2 122	2 333
Total equity and liabilities	**25 655**	**23 428**	**25 906**	**27 110**

CONSOLIDATED CHANGES IN EQUITY IN SUMMARY

All amounts in SEK thousand	2026-06-30	2025-06-30	2026-03-31	2025-12-31
Opening balance	23 344	19 988	23 344	19 988
New share issues			-	3 896
New Issue - Not reg.ShareCapital		4 314	-	11 417
Costs of new share issues			-	-20
Profit/loss for the period	-9 103	-5 212	-3 626	-12 167
Other comprehensive income for the period	903		814	230
Closing balance	**15 144**	**19 090**	**20 532**	**23 344**

QUARTERLY EARNINGS DEVELOPMENT

All amounts in SEK thousand	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	13	835	356	400	334	812	269	268	328	416
Gross profit/loss	5	449	224	151	277	240	44	213	157	340
Gross margin in %	38%	54%	63%	38%	83%	30%	16%	79%	48%	82%
Operating profit/loss	-5 514	-3 658	-5 867	-1 029	-3 148	-2 104	-2 764	-2 942	-3 136	-2 205
Profit/loss for the period	-5 477	-3 626	-5 925	-1 030	-3 149	-2 063	-2 610	-3 008	-3 157	-2 179
Cash flow	488	-1 966	528	1 072	-1 369	-932	2 171	-3 951	4 245	-427

CASH FLOW STATEMENT IN SUMMARY – GROUP

All amounts in SEK thousand	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Profit/loss after financial items	-5 477	-3 149	-9 103	-5 212	-12 167
Adjustments for non-cash items	527	228	1 643	300	1 304
Tax paid	-	-	-	-	-
Cash flow from operating activities before changes in working capital	**-4 950**	**-2 921**	**-7 460**	**-4 912**	**-10 863**
Changes in working capital	1 629	-2 854	585	-888	686
Cash flow from operating activities	**-3 321**	**-5 775**	**-6 875**	**-5 800**	**-10 177**
Capitalization of development expenditure	-1 191	134	-1 603	-690	-3 566
Acquisition/disposal of intangible assets	-		-		-
Acquisition/disposal of property, plant & equipment	-	-42	-	-125	-
Acquisition/disposal of financial assets	-		-		-
Cash flow from investing activities	**-1 191**	**92**	**-1 603**	**-815**	**-3 566**
New share issue	-	4 314	-	4 314	15 312
Transaction costs attributable to new share issue	-		-		-20
Change in bank overdraft facilities	5 000		7 000		0
Amortization in bank overdraft facilities	-		-		-2 250
Cash flow from financing activities	**5 000**	**4 314**	**7 000**	**4 314**	**13 042**
Total cash flow for the period	**488**	**-1 369**	**-1 478**	**-2 301**	**-701**
Cash and cash equivalents at start of period	522	2 257	2 488	3 189	3 189
Cash and cash equivalents at end of period	**1 010**	**888**	**1 010**	**888**	**2 488**

PARENT COMPANY' S INCOME STATEMENT

All amounts in SEK thousand	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating income					
Net sales	13	334	843	1 140	1 878
Cost of goods sold	-8	-54	-390	-592	-797
Gross profit	**5**	**280**	**453**	**548**	**1 081**
External expenses	-4 070	-1 517	-6 034	-2 823	-8 125
Staff expenses	-1 404	-1 948	-3 578	-3 054	-4 972
R&D Expenses	-1 191	0	-1 603	-816	-3 566
Capitalized development expenditure	1 191	0	1 603	816	3 566
Other operating income	61	118	131	187	262
Other operating expenses	-30	-6	-30	-6	-323
Operating profit/loss	**-5 438**	**-3 073**	**-9 058**	**-5 148**	**-12 077**
Interest income and similar profit/loss items	37	1	74	43	192
Interest expenses and similar profit/loss items	0		-5	-1	-209
Profit/loss after financial items	**-5 401**	**-3 072**	**-8 989**	**-5 106**	**-12 094**
Tax expenses	-	-	-	-	-
Profit/loss for the period	**-5 401**	**-3 072**	**-8 989**	**-5 106**	**-12 094**

PARENT COMPANY'S BALANCE SHEET

All amounts in SEK thousand	2026-06-30	2025-06-30	2026-03-31	2025-12-31
Assets				
Intangible assets	10 446	7 529	9 652	9 544
Property, plant & equipment	140	218	180	180
Financial assets	10 000	10 000	10 000	10 000
Inventories	1 331	1 069	1 231	1 331
Trade receivables	765	1 587	2 559	2 074
Receivables from group companies	2 559	2 907	2 561	3 199
Other receivables	1 289	1 410	1 086	877
Cash and bank balances	583	458	50	1 560
Total assets	**27 113**	**25 178**	**27 319**	**28 765**
Equity and liabilities				
Equity	16 632	20 856	22 073	24 846
Interest-bearing liabilities, longterm	0	0	0	0
Current interest-bearing liabilities	7 000	2 250	2 000	0
Liabilities to group companies	0	0	0	204
Trade payables	579	815	1 252	1 433
Other liabilities	2 902	1 257	1 994	2 282
Total equity and liabilities	**27 113**	**25 178**	**27 319**	**28 765**